Saturday 17 October 2026
Export MDRX’s income statement to Excel — free account
Veradigm Inc.
MDRX Healthcare Health Information Services
5.00
0.00
0.00%
Follow MDRX
| Older periods | Mar '22 | Jun '22 | Sep '22 | Dec '22 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.46 | 29.66 | 30.46 | 0.00 |
P/S ratio |
4.45 | 2.84 | 2.78 | 3.28 | |
P/FCF ratio |
0.00 | 11.85 | 14.25 | 22.83 | |
P/Operating CF |
37.67 | (1,036.29) | 59.64 | 91.66 | |
P/B ratio |
1.93 | 1.42 | 1.43 | 1.90 | |
Price to Tangible BV |
3.87 | 3.24 | 3.31 | 4.88 | |
EV/Sales |
5.03 | 2.42 | 2.38 | 2.94 | |
EV/EBITDA |
20.18 | 11.84 | 11.38 | 22.08 | |
EV/Operating CF |
(247.32) | 7.69 | 8.98 | 14.82 | |
EV/FCF |
(53.76) | 10.07 | 12.17 | 20.47 | |
Quick Ratio |
0.39 | 2.61 | 2.62 | 2.46 | |
Current Ratio |
2.38 | 3.23 | 3.20 | 2.95 | |
Net Debt/EBITDA |
14.17 | (33.48) | (7.56) | (25.06) | |
Debt/Assets |
15.52% | 11.66% | 11.85% | 13.32% | |
Debt/Equity |
0.28 | 0.17 | 0.17 | 0.20 | |
Asset Turnover |
0.22 | 0.28 | 0.29 | 0.31 | |
Operating CF/Net income |
3.03 | 0.03 | 1.94 | (0.35) | |
Capex/Depreciation |
(0.71) | (0.69) | (0.59) | (0.07) | |
Interest Coverage |
3.08 | (2.84) | 20.07 | (49.14) | |
Research and Development Expense of Revenue |
16.42% | 15.08% | 15.59% | 19.67% | |
Selling, General and Administrative Expense of Revenue |
28.96% | 39.66% | 21.40% | 24.92% | |
Intangible Assets out of Total Assets |
0.28 | 0.39 | 0.40 | 0.41 | |
Share Based Compensation of Revenue |
4.43% | 5.98% | 3.00% | 3.66% | |
Graham Net Nets |
0.18 | 0.18 | 0.18 | 0.10 | |
Graham Number |
17.90 | 10.85 | 10.96 | 0.00 | |
Earnings Yield |
5.42% | 3.37% | 3.28% | (4.47%) | |
Free Cash Flow Yield |
(2.10%) | 8.44% | 7.02% | 4.38% | |
Revenue per Share |
1.23 | 1.32 | 1.38 | 1.27 | |
Operating CF per Share |
0.60 | (0.01) | 0.26 | 0.19 | |
Capex per Share |
(0.09) | (0.09) | (0.07) | (0.04) | |
Free Cash Flow per Share |
0.51 | (0.10) | 0.18 | 0.15 | |
Cash per Share |
0.73 | 4.39 | 4.48 | 4.00 | |
Shareholders Equity per Share |
11.68 | 10.47 | 10.68 | 9.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.68 | 10.47 | 10.68 | 9.08 | |
Free Cash Flow |
59.32 | (11.60) | 19.97 | 16.87 | |
Working Capital |
893.83 | 572.44 | 557.68 | 449.34 | |
Capital Expenditures |
(9.94) | (9.96) | (8.17) | (4.18) | |
Net Current Asset Value |
463.54 | 310.90 | 297.13 | 192.43 | |
EV/EBIT |
39.02 | 26.97 | 23.90 | 0.00 | |
Capex to Sales |
0.07 | 0.07 | 0.05 | 0.03 | |
Price to Operating Income |
34.51 | 31.71 | 28.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
277.49 | 252.67 | 254.98 | 119.42 | |
Average Payables |
21.22 | 22.40 | 17.21 | 16.51 | |
Average Assets |
2,650.82 | 2,127.26 | 2,087.48 | 1,907.87 | |
Average Common Equity |
1,515.88 | 1,294.91 | 1,297.81 | 1,188.94 |
Columns are period end dates · fundamentals updated 1 Oct 2026